J&J COVID-19 booster cuts Omicron hospitalizations by 84%, study suggests
The real-world study was based on a second dose of the Johnson & Johnson vaccine administered to 69,092 workers between Nov. 15 and Dec. 20.
Tomas Kauer - Moderator 
The real-world study was based on a second dose of the Johnson & Johnson vaccine administered to 69,092 workers between Nov. 15 and Dec. 20.
:quality(85):upscale()/2024/04/22/931/n/1922283/abb74e546626d4adbd7255.17882634_.jpg){kind=small}
:quality(85):upscale()/2024/12/02/919/n/1922398/2b4b75f6674e20edcc99c3.42112799_.jpg)
:quality(85):upscale()/2024/09/04/734/n/1922283/9b8f37ec66d88cf7b7e084.15655484_.jpg)
